Dechra Pharmaceuticals PLC
DCHPF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.00 | 10.14 | 1.57 | 8.40 |
| FCF Yield | 0.82% | 1.31% | 2.04% | 2.01% |
| EV / EBITDA | 51.60 | 20.56 | 30.60 | 22.71 |
| Quality | ||||
| ROIC | 0.35% | 6.29% | 5.94% | 3.92% |
| Gross Margin | 55.98% | 56.44% | 56.89% | 56.61% |
| Cash Conversion Ratio | 10.10 | 1.29 | 1.61 | 2.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.79% | 9.80% | 8.06% | 8.16% |
| Free Cash Flow Growth | -26.49% | -53.29% | 69.54% | -3.54% |
| Safety | ||||
| Net Debt / EBITDA | 4.96 | 1.16 | 1.24 | 0.97 |
| Interest Coverage | 0.14 | 7.83 | 8.57 | 4.54 |
| Efficiency | ||||
| Inventory Turnover | 1.54 | 1.69 | 1.75 | 1.85 |
| Cash Conversion Cycle | 258.48 | 224.76 | 212.12 | 197.04 |